Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice

Giovanni Caocci, Olga Mulas, Elisabetta Abruzzese, Alessandra Iurlo, Mario Annunziata, Ester Maria Orlandi, Sara Galimberti, Gianni Binotto, Nicola Sgherza, Luigia Luciano, Bruno Martino, Antonella Russo Rossi, Massimiliano Bonifacio, Claudio Fozza, Malgorzata Monika Trawinska, Daniele Cattaneo, Chiara Elena, Claudia Baratè, Fiorenza De Gregorio, Matteo MolicaGiorgio La Nasa, Robin Foà, Massimo Breccia

Research output: Contribution to journalArticlepeer-review

Abstract

There is little information about cardiovascular adverse event (CV-AE) incidence in chronic myeloid leukemia (CML) patients treated with bosutinib in the real-life practice. We identified 54 consecutive CML patients treated with bosutinib, stratified according to the Systematic Coronary Risk Evaluation (SCORE) assessment, based on sex, age, smoking habits, systolic blood pressure, and total cholesterol levels. The 40-month cumulative incidence of CV-AEs was 25.2 ± 8.1%. Patients with the SCORE of high-very high showed a significantly higher incidence of CV-AEs (55 ± 12.9% vs 9 ± 9.5%; p = 0.002). Overall, 9 CV-AEs were reported, with 2 deaths attributed to CV-AE. In conclusion, the SCORE assessment before starting treatment is helpful in identifying CV-AE high-risk patients during bosutinib treatment.
Original languageEnglish
Pages (from-to)1885-1890
Number of pages6
JournalAnnals of Hematology
Volume98
Issue number8
DOIs
Publication statusPublished - Aug 2019

Keywords

  • Acetylsalicylic acid
  • Bosutinib
  • Cardiovascular risk
  • Chronic myeloid leukemia
  • Adult
  • Aged
  • Aged, 80 and over
  • Angina Pectoris/chemically induced/diagnosis/physiopathology
  • Aniline Compounds/administration & dosage/*adverse effects
  • Antineoplastic Agents/administration & dosage/*adverse effects
  • Brain Ischemia/chemically induced/diagnosis/physiopathology
  • Dasatinib/administration & dosage/adverse effects
  • Disease Susceptibility
  • Drug Administration Schedule
  • Female
  • Humans
  • Imatinib Mesylate/administration & dosage/adverse effects
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy/enzymology/pathology
  • Male
  • Middle Aged
  • Myocardial Infarction/*chemically induced/diagnosis/physiopathology
  • Nitriles/administration & dosage/*adverse effects
  • Peripheral Vascular Diseases/chemically induced/diagnosis/physiopathology
  • Protein Kinase Inhibitors/administration & dosage/*adverse effects
  • Pyrimidines/administration & dosage/adverse effects
  • Quinolines/administration & dosage/*adverse effects
  • Retrospective Studies

Fingerprint

Dive into the research topics of 'Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice'. Together they form a unique fingerprint.

Cite this